Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Latest From Bayer AG

Quality Officers Call For New Approaches To Reduce Global Manufacturing Change Complexity

Pharmaceutical quality leadership proposes eight-step “dance” with complex global regulatory system for allowing manufacturing processes to improve more quickly. The data showed many authorities take more than the recommended six months to decide on post-approval changes, with assessments taking almost eight years in some cases.

Manufacturing Quality

News We're Watching: Tricuspid Procedure Boom, Boston Scientific Borrows $2Bn, And More

Medtech Insight's News We're Watching highlights some recent business and R&D developments you may have missed. This week, GE Healthcare and Biofourmis announced a deal to collaborate on virtual care; Cleerly touts a new CPT code for its Ischemia cardiac diagnostic software; Boston Scientific announced how it plans to pay for Axonics; a Wells Fargo survey suggests the market for transcatheter tricuspid valve repair and replacement will grow faster than previously imagined; Virtual Incision earns FDA de novo authorization for its MIRA miniaturized surgical system for colectomy procedures; and MMI and Fabric announce major financing rounds.

News We're Watching Approvals

Bayer Cuts Dividend To The Bone To Cut Debt

The embattled German major is touting a promising mid-stage thrombolytic but the spotlight this week has continued to shine on its business model and high levels of debt.

Business Strategies Restructuring

Bayer’s BD And Licensing Strategy Key To Moving Through Difficult Period

As Bayer moves through a challenging period, business development, licensing and impact investment may help buttress the company’s resilience

C-Suite Speaks Business Strategies
See All

Company Information

  • Industry
  • In Vitro Diagnostics
  • Pharmaceuticals
  • Pharmaceuticals
    • OTC, Consumer
    • Radiopharmaceuticals, Contrast Agents
  • Digital Health
    • Artificial Intelligence
  • Other Names / Subsidiaries
    • Actus Therapeutics, Inc.
    • AskBio
    • Asklepios BioPharmaceutical, Inc.
    • Synpromics, Ltd.
    • RoverMed BioSciences
    • NanoCor Therapeutics
    • BrainVectis
    • Algeta ASA
    • Bayer CropScience AG
    • Bayer Consumer Care AG
    • Berlex Laboratories
    • BlueRock Therapeutics
    • Conceptus Inc.
    • Dihon Pharmaceutical Group Co., Ltd.
    • Intendis GmbH
    • Jenapharm
    • Medrad Inc.
    • Possis Medical
    • Schering AG
    • Monsanto Company
    • Zeptosens AG
    • KaNDy Therapeutics
    • Vividion Therapeutics, Inc.
UsernamePublicRestriction

Register